Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51,976 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B; EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Panitch H, et al. Among authors: li d. J Neurol Sci. 2005 Dec 15;239(1):67-74. doi: 10.1016/j.jns.2005.08.003. Epub 2005 Sep 19. J Neurol Sci. 2005. PMID: 16169561 Clinical Trial.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B; EVIDENCE Study Group. EVidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Panitch H, et al. Among authors: li d. Neurology. 2002 Nov 26;59(10):1496-506. doi: 10.1212/01.wnl.0000034080.43681.da. Neurology. 2002. PMID: 12451188 Clinical Trial.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G; EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group. Schwid SR, et al. Among authors: li d. Arch Neurol. 2005 May;62(5):785-92. doi: 10.1001/archneur.62.5.785. Arch Neurol. 2005. PMID: 15883267 Clinical Trial.
Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
Traboulsee A, Al-Sabbagh A, Bennett R, Chang P, Li DK; EVIDENCE Study Group; UBC MS/MRI Research Group. Traboulsee A, et al. Among authors: li dk. BMC Neurol. 2008 Apr 21;8:11. doi: 10.1186/1471-2377-8-11. BMC Neurol. 2008. PMID: 18426595 Free PMC article. Clinical Trial.
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study.
Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, Sandberg-Wollheim M, Traboulsee A, Verdun E, Rivera V. Uitdehaag B, et al. Among authors: li d. Ther Adv Neurol Disord. 2011 Jan;4(1):3-14. doi: 10.1177/1756285610391693. Ther Adv Neurol Disord. 2011. PMID: 21339904 Free PMC article.
51,976 results
You have reached the last available page of results. Please see the User Guide for more information.